Japan approves rheumatoid drug Baricitinib for COVID-19 patients

mediabest

TOKYO (Reuters) – Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.

Eli Lilly & Co’s Japan subsidiary had applied to regulators for the new use of the drug in December.

Source: Read Full Article

Related posts:
  1. Japan set to extend state of emergency, likely for another month
  2. Japan's vaccine minister says inoculation pace to accelerate in May
  3. Japan getting more Pfizer COVID-19 vaccines to immunise elderly faster
  4. Sinopharm, Sinovac COVID-19 vaccine data show efficacy: WHO
  5. Michigan hits top of list of U.S. states for new COVID-19 cases